Material Event Form 8 K

As previously disclosed, on July 11, 2024, Unicycive Therapeutics, Inc. (the "Company") received a written notice (the "Notice") from the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(b)(2) (the "Rule"), since it had failed to maintain a minimum market value of listed securities of $35,000,000 over the previous 30 consecutive business days.

Nasdaq has determined that for the last 10 consecutive business days, from September 10 to September 23, 2024, the Company's market value of listed securities has been $35,000,000 or greater. On September 24, 2024, the Company received notice from Nasdaq that the Company has regained compliance with the minimum market value requirement for continued listing on The Nasdaq Capital Market.